GSK has reported new clinical data pointing to a benefit with its respiratory syncytial virus (RSV) vaccine Arexvy when used to treat a younger age group than the over-60s for whom it is approved.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback